Novel anti-tubulin cytotoxic agents for breast cancer Journal Article
| Authors: | Morris, P. G.; Fornier, M. N. |
| Article Title: | Novel anti-tubulin cytotoxic agents for breast cancer |
| Abstract: | Regardless of stage of disease, cytotoxic chemotherapy remains an important part of the treatment paradigm for breast cancer. Anthracyclines and taxanes are the most active agents; however, limitations with their use exist. These include a maximum lifetime dose and tumor resistance with anthracycline, hypersensitivity reactions and cumulative toxicity with taxanes. Therefore, to meet these challenges, the development of new cytotoxics and novel taxane formulations is an important area of active research. Several recent advances have been made. Epothilones represent a novel group of cytotoxic agents, with proven activity in breast cancer. Nanoparticle drug delivery systems have led to the development of ABI-007, which has demonstrated superior response rates than 3-weekly paclitaxel, with a lower risk of hypersensitivity reactions. To circumvent the problem of taxane resistance, larotaxel, a semisynthetic taxoid, and vinflunine, a synthetic vinca alkaloid, have been developed with encouraging clinical results to date. Eribulin, a synthetic derivative of halichondrin has recently entered Phase III trials based on encouraging activity in heavily pretreated patients. A further novel approach is the conjugation of cytotoxic agents to targeted agents, such as with trastuzumab-MCC-DM1. Elucidating the relative importance of these agents and incorporating them into existing treatment paradigms is a significant challenge for the future. © 2009 Expert Reviews Ltd. |
| Keywords: | vasculotropin; cancer chemotherapy; cancer survival; unclassified drug; clinical trial; constipation; fatigue; neutropenia; review; sorafenib; bevacizumab; cisplatin; cytotoxic agent; doxorubicin; diarrhea; drug dose reduction; drug potentiation; drug withdrawal; monotherapy; nonhuman; recommended drug dose; side effect; solid tumor; antineoplastic agents; clinical trials as topic; pathophysiology; capecitabine; gemcitabine; paclitaxel; adjuvant therapy; neurotoxicity; antineoplastic agent; progression free survival; apoptosis; infection; multiple cycle treatment; sensory neuropathy; breast cancer; protein targeting; blood toxicity; gastrointestinal symptom; leukopenia; mucosa inflammation; nausea; stomatitis; vomiting; myalgia; peripheral neuropathy; drug dosage form comparison; antineoplastic activity; cytotoxicity; drug screening; breast neoplasms; bladder cancer; docetaxel; drug dose escalation; drug hypersensitivity; febrile neutropenia; injection site reaction; drug delivery systems; drug fatality; albumins; dosage schedule comparison; breast tumor; drug response; hypoglycemia; microtubule assembly; nanoparticles; nanoparticle; taxoids; vinca alkaloid; metastasis potential; maximum tolerated dose; sensory dysfunction; tumor growth; corticosteroid; trastuzumab; navelbine; ileus; drug delivery system; furan derivative; furans; ixabepilone; sagopilone; epothilones; 21 aminoepothilone b; 9,10 didehydroepothilone d; epothilone b; epothilone d; epothilone derivative; tubulin modulator; tubulin modulators; abi-007; epothilone; eribulin; larotaxel; paclitaxel poliglumex; taxane resistance; trastuzumab-mcc-dm1; vinflunine; antihistaminic agent; dm1; maytansine; rpr 109881a; 2 (3 amino 2 hydroxypropyl)hexacosahydro 3 methoxy 26 methyl 20,27 bis(methylene)11,15 18,21 24,28 triepoxy 7,9 ethano 12,15 methano 9h,15h furo(3,2 i)furo(2',3' 5,6)pyrano(4,3 b)(1,4)dioxacyclopentacosin 5 (4h) one; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4h)-one; albumin bound paclitaxel; albumin-bound paclitaxel; albuminoid; ketone; taxoid; drug formulation; fluid retention; keratitis; ketones; vinca alkaloids |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 9 |
| Issue: | 2 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2009-02-01 |
| Start Page: | 175 |
| End Page: | 185 |
| Language: | English |
| DOI: | 10.1586/14737140.9.2.175 |
| PUBMED: | 19192956 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 12" - "Export Date: 30 November 2010" - "CODEN: ERATB" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work